These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 12173326)

  • 1. Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival.
    Pelger RC; Lycklama A Nijeholt Ga; Zwinderman AH; Hamdy NA
    Cancer; 2002 May; 94(10):2596-601. PubMed ID: 12173326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group.
    Janknegt RA; Boon TA; van de Beek C; Grob P
    Urology; 1997 Mar; 49(3):411-20. PubMed ID: 9123707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The flare in alkaline phosphatase activity post-orchidectomy predicts which patient may benefit from early chemotherapy in metastatic prostate cancer.
    Pelger RC; Lycklama A Nijeholt GA; Zwinderman AH; Hamdy NA
    Prostate; 2002 Feb; 50(2):119-24. PubMed ID: 11816020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular changes in prostatic carcinoma after treatment with orchidectomy, estramustine phosphate and medroxyprogesterone acetate.
    Tomic R; Angström T; Ljungberg B
    Scand J Urol Nephrol; 1997 Jun; 31(3):255-8. PubMed ID: 9249888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.
    Iversen P; Rasmussen F; Asmussen C; Christensen IJ; Eickhoff J; Klarskov P; Larsen E; Mogensen P; Mommsen S; Rosenkilde P
    J Urol; 1997 Mar; 157(3):929-34. PubMed ID: 9072602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience in advanced prostatic cancer: orchiectomy and flutamide versus orchiectomy and estramustine phosphate.
    Roessler W; Hinke A; Wieland WF
    Urology; 1994 Feb; 43(2 Suppl):57-60. PubMed ID: 8116134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer].
    Matsuda H; Nonomura K; Nagamori S; Shinohara N; Koyanagi T; Maru A; Matsuno T; Fujieda J; Minami S; Morita H
    Nihon Hinyokika Gakkai Zasshi; 1995 Oct; 86(10):1530-7. PubMed ID: 7474602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.
    Garcia JA; Weinberg V; Small EJ
    Clin Prostate Cancer; 2005 Sep; 4(2):113-7. PubMed ID: 16197612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of disseminated prostate cancer with estramustine.
    Rosenthal MA; Raghavan D; Stuart-Harris R; Ackland S; Grygiel J
    Aust N Z J Surg; 1992 Nov; 62(11):871-3. PubMed ID: 20169706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.
    Matsumoto K; Tanaka N; Hayakawa N; Ezaki T; Suzuki K; Maeda T; Ninomiya A; Nakamura S
    Med Oncol; 2013 Dec; 30(4):717. PubMed ID: 24005812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The place of estramustine in the treatment of prostate cancer].
    Pintér O; Tóth C; Szabó Z; Lipták J; Fél P; Papp G; Holman E; Hazay L; Streit B; Kisbenedek L; Fehér M; Kocsis I
    Orv Hetil; 2005 Mar; 146(12):553-7. PubMed ID: 15853064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of second line estramustine for overall survival of hormone-refractory prostate cancer (HRPC) patients.
    Naiki T; Okamura T; Kawai N; Sakagami H; Yamada Y; Fujita K; Akita H; Hashimoto Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2009; 10(1):71-4. PubMed ID: 19469628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study.
    Hagiwara K; Koie T; Ohyama C; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Tobisawa Y; Yoneyama T
    Int Urol Nephrol; 2017 May; 49(5):811-816. PubMed ID: 28213801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy for clinical localized prostate cancer treated with surgery or irradiation.
    Schmidt JD; Gibbons RP; Murphy GP; Bartolucci A
    Eur Urol; 1996; 29(4):425-33. PubMed ID: 8791049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].
    Murachi K; Kumagai T; Masuda T; Nakanishi T; Tanaka S; Tajima K; Takebe Y; Oda T
    Hinyokika Kiyo; 2016 Jun; 62(6):295-306. PubMed ID: 27452492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized comparative study of endocrine monotherapy and a combination of estramustine phosphate with the endocrine therapy in patients with untreated stage D prostate cancer.
    Hoshi S; Yamaguchi O; Fujioka T; Arai Y; Tomita Y; Habuchi T; Ohyama C; Suzuki T; Orikasa S;
    Int J Clin Oncol; 2006 Aug; 11(4):303-8. PubMed ID: 16937304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of estramustine phosphate according to risk classification of castration-resistant prostate cancer.
    Minato A; Fujimoto N; Kubo T; Harada S; Akasaka S; Matsumoto T
    Med Oncol; 2012 Dec; 29(4):2895-900. PubMed ID: 22323054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
    Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
    Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Necessity of re-evaluation of estramustine phosphate sodium (EMP) as a treatment option for first-line monotherapy in advanced prostate cancer.
    Kitamura T
    Int J Urol; 2001 Feb; 8(2):33-6. PubMed ID: 11240822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.